Generelt optrådte bivirkningerne hyppigere blandt ældre patienter og patienter med nedsat nyrefunktion, men bivirkningerne var de samme i disse undergrupper som dem, der ses i den almindelige befolkning.
In general, adverse events occurred more frequently among elderly patients and patients with renal impairment; however, the types of events in these subgroups were similar to those observed in the general population.